163 related articles for article (PubMed ID: 29935395)
21. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.
Rasmussen ELK; Hannibal CG; Dehlendorff C; Baandrup L; Junge J; Vang R; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Mar; 144(3):571-576. PubMed ID: 28108026
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT
Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
[TBL] [Abstract][Full Text] [Related]
23. The role of the fallopian tube in ovarian cancer.
Tone AA; Salvador S; Finlayson SJ; Tinker AV; Kwon JS; Lee CH; Cohen T; Ehlen T; Lee M; Carey MS; Heywood M; Pike J; Hoskins PJ; Stuart GC; Swenerton KD; Huntsman DG; Gilks CB; Miller DM; McAlpine JN
Clin Adv Hematol Oncol; 2012 May; 10(5):296-306. PubMed ID: 22706539
[TBL] [Abstract][Full Text] [Related]
24. The fallopian tube: primary site of most pelvic high-grade serous carcinomas.
Salvador S; Gilks B; Köbel M; Huntsman D; Rosen B; Miller D
Int J Gynecol Cancer; 2009 Jan; 19(1):58-64. PubMed ID: 19258943
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for benign serous and mucinous epithelial ovarian tumors.
Jordan SJ; Green AC; Whiteman DC; Webb PM
Obstet Gynecol; 2007 Mar; 109(3):647-54. PubMed ID: 17329516
[TBL] [Abstract][Full Text] [Related]
26. Increased risk for ovarian cancer and borderline ovarian tumours in subfertile women with endometriosis.
Buis CC; van Leeuwen FE; Mooij TM; Burger CW;
Hum Reprod; 2013 Dec; 28(12):3358-69. PubMed ID: 24014607
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
Dao F; Schlappe BA; Tseng J; Lester J; Nick AM; Lutgendorf SK; McMeekin S; Coleman RL; Moore KN; Karlan BY; Sood AK; Levine DA
Gynecol Oncol; 2016 May; 141(2):260-263. PubMed ID: 26968641
[TBL] [Abstract][Full Text] [Related]
28. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
[TBL] [Abstract][Full Text] [Related]
29. Pelvic inflammatory disease and risk of epithelial ovarian cancer: a national population-based case-control study in Sweden.
Jonsson S; Jonsson H; Lundin E; Häggström C; Idahl A
Am J Obstet Gynecol; 2024 Jan; 230(1):75.e1-75.e15. PubMed ID: 37778677
[TBL] [Abstract][Full Text] [Related]
30. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
[TBL] [Abstract][Full Text] [Related]
31. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis.
Jordan SJ; Green AC; Whiteman DC; Moore SP; Bain CJ; Gertig DM; Webb PM; ;
Int J Cancer; 2008 Apr; 122(7):1598-603. PubMed ID: 18058817
[TBL] [Abstract][Full Text] [Related]
32. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.
Phung MT; Webb PM; DeFazio A; Fereday S; Lee AW; Bowtell DDL; Fasching PA; Goode EL; Goodman MT; Karlan BY; Lester J; Matsuo K; Modugno F; Brenton JD; Van Gorp T; Pharoah PDP; Schildkraut JM; McLean K; Meza R; Mukherjee B; Richardson J; Grout B; Chase A; McKinnon Deurloo C; Terry KL; Hanley GE; Pike MC; Berchuck A; Ramus SJ; Pearce CL;
Gynecol Oncol; 2023 Jan; 168():68-75. PubMed ID: 36401943
[TBL] [Abstract][Full Text] [Related]
33. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
Zhu YF; He LS; Zhang ZD; Huang QS
Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
[TBL] [Abstract][Full Text] [Related]
34. Ovarian cancer: etiology, risk factors, and epidemiology.
Hunn J; Rodriguez GC
Clin Obstet Gynecol; 2012 Mar; 55(1):3-23. PubMed ID: 22343225
[TBL] [Abstract][Full Text] [Related]
35. Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones.
Harlow BL; Weiss NS; Roth GJ; Chu J; Daling JR
Cancer Res; 1988 Oct; 48(20):5849-52. PubMed ID: 3167840
[TBL] [Abstract][Full Text] [Related]
36. The risk of breast and gynecological cancer in women with a diagnosis of infertility: a nationwide population-based study.
Lundberg FE; Iliadou AN; Rodriguez-Wallberg K; Gemzell-Danielsson K; Johansson ALV
Eur J Epidemiol; 2019 May; 34(5):499-507. PubMed ID: 30623293
[TBL] [Abstract][Full Text] [Related]
37. Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
Hou X; Zhai Y; Hu K; Liu CJ; Udager A; Pearce CL; Fearon ER; Cho KR
Gynecol Oncol; 2022 Jun; 165(3):552-559. PubMed ID: 35414426
[TBL] [Abstract][Full Text] [Related]
38. Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas.
Gilks CB; Irving J; Köbel M; Lee C; Singh N; Wilkinson N; McCluggage WG
Am J Surg Pathol; 2015 Mar; 39(3):357-64. PubMed ID: 25517954
[TBL] [Abstract][Full Text] [Related]
39. Pelvic inflammatory disease and risk of ovarian cancer.
Parazzini F; La Vecchia C; Negri E; Moroni S; dal Pino D; Fedele L
Cancer Epidemiol Biomarkers Prev; 1996 Aug; 5(8):667-9. PubMed ID: 8824371
[TBL] [Abstract][Full Text] [Related]
40. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
